ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 ... ( NEW ORLEANS M The results from t...)

HOME >> MEDICINE >> TECHNOLOGY

ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference

Date:5/4/2010

NEW ORLEANS, May 4 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%. The difference in remission rate between the two groups was statistically significant (p=0.01) at week 36. Also, at week 36, a statistically significant percentage of patients receiving Traficet-EN versus placebo were in corticosteroid-free remission and had normalized C-reactive protein (CRP) levels. Traficet-EN continued to be safe and well-tolerated for the entire course of the PROTECT-1 study (aggregate dosing up to one year). These data were presented today in an oral session at the Digestive Disease Week (DDW) conference in New Orleans by Satish Keshav, M.D., Ph.D., Department of Gastroenterology, John Radcliffe Hospital, Oxford University.

The results from the Maintenance period of PROTECT-1 reported here confirmed and expanded the efficacy of Traficet-EN that was observed in the preceding Induction period of the study, which was reported in 2009.

"Treatment for inflammatory diseases of the bowel including Crohn's has been woefully insufficient for far too long for such a devastating disease," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "We believe Traficet-EN represents a paradigm shift in terms of safety and efficacy for these patients, of
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones

Post Your Comments:

(Date:5/23/2013)... 23, 2013 PAREXEL International Corporation (NASDAQ: ... at the Jefferies Healthcare Conference in New York. ... Chief Financial Officer, will be making a presentation on ... Monday, June 3, 2013. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...

(Date:5/22/2013)... , May 22, 2013 Aribex, Inc., manufacturer of ... today introduced a new color option, black with gray ... dental and veterinary markets. The popular white with light ... will continue to be available and both models can ... (Photo: http://photos.prnewswire.com/prnh/20130522/CL19573 ) "Dental ...

(Date:5/22/2013)... NEW YORK , May 22, 2013 /PRNewswire/ ... is investigating potential claims on behalf of purchasers ... or the "Company") (NasdaqGS: AMAG -News). The investigation ... violated federal securities laws. On May ... 10.73% during intraday trading after the company announced ...

Breaking Medicine Technology:PAREXEL International To Present At Jefferies Healthcare Conference 2 Aribex Unveils New Color of NOMAD Pro 2 2 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2

[0] PAREXEL International To Present At Jefferies Healthcare Conference [0] Aribex Unveils New Color of NOMAD Pro 2 [0] Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.

... 2010 Express Scripts, Inc. (Nasdaq: ... Scripts Specialty Benefit Services, the industry,s most comprehensive ... sponsors a first-in-the-industry offering that enhances patient care ... the specialty medical drug spend. (Logo: ...

... Advanced Life Sciences Holdings, Inc. (OTC ... engaged in the discovery, development and commercialization of novel ... respiratory diseases, today announced that the Company has applied ... drug designation for ALS-886, a novel therapy to reduce ...

Cached Medicine Technology:Express Scripts Establishes Industry's Most Comprehensive Specialty Benefits Organization; Enhances Patient Care and Guarantees Cost Savings 2 Express Scripts Establishes Industry's Most Comprehensive Specialty Benefits Organization; Enhances Patient Care and Guarantees Cost Savings 3 Express Scripts Establishes Industry's Most Comprehensive Specialty Benefits Organization; Enhances Patient Care and Guarantees Cost Savings 4 Advanced Life Sciences Applies for FDA Orphan Drug Designation for ALS-886 to Treat Acute Lung Injury 2 Advanced Life Sciences Applies for FDA Orphan Drug Designation for ALS-886 to Treat Acute Lung Injury 3 Advanced Life Sciences Applies for FDA Orphan Drug Designation for ALS-886 to Treat Acute Lung Injury 4

Express Scripts Establishes Industry's Most Comprehensive Specialty Benefits Organization; Enhances Patient Care and Guarantees Cost Savings Advanced Life Sciences Applies for FDA Orphan Drug Designation for ALS-886 to Treat Acute Lung Injury

(Date:5/23/2013)... May 23, 2013 Wei Angela Liu, ... Phelps Memorial Hospital Center as Medical Director of ... comprehensive inpatient and outpatient rehabilitation care to patients of ... received her undergraduate degree in biochemistry at Columbia College, ... She earned her medical degree at New York ...

(Date:5/23/2013)... Cedar Rapids, IA (PRWEB) May 23, 2013 ... the Creative Corridor have an expanded understanding of diversity. ... The survey was done from February-March of this year. ... the survey as a follow up to its benchmark survey ... two top factors reported in the definition of diversity were ...

(Date:5/23/2013)... to moderate iodine deficiency during pregnancy may have a ... report. Low levels of the so-called "trace element" ... child at risk of poorer verbal and reading skills ... women can boost their iodine levels by eating enough ... finding, published online May 22 in The Lancet ...

(Date:5/23/2013)... Reinberg HealthDay Reporter , , THURSDAY, May 23 ... may be at increased risk for cancers of the ... or drink alcohol, a new study says. Interestingly, ... while prescription medications such as Prilosec, Nexium and Prevacid ... controversy about whether heartburn contributes to cancers of the ...

(Date:5/23/2013)... dementia are less stressed and their moods are ... day services (ADS), according to Penn State researchers. ... someone with dementia can experience extraordinary amounts of ... development and family studies. "The use of adult ... much-needed break that can possibly protect them from ...

Breaking Medicine News(10 mins):Health News:Wei Angela Liu, MD, Named Head of Physical Medicine and Rehabilitation at Phelps Memorial Hospital Center in Sleepy Hollow, New York 2 Health News:Diversity Focus Announces Results from the 2013 Creative Corridor Community Survey 2 Health News:Low Prenatal Iodine May Affect Child's Brain Development 2 Health News:Chronic Heartburn May Raise Odds for Throat Cancer: Study 2 Health News:Adult day services for dementia patients provide stress relief to family caregivers 2

[0] Wei Angela Liu, MD, Named Head of Physical Medicine and Rehabilitation at Phelps Memorial Hospital Center in Sleepy Hollow, New York [0] Diversity Focus Announces Results from the 2013 Creative Corridor Community Survey [0] Low Prenatal Iodine May Affect Child's Brain Development [0] Chronic Heartburn May Raise Odds for Throat Cancer: Study [0] Adult day services for dementia patients provide stress relief to family caregivers

... criteria for full alert, agency says , TUESDAY, June 9 ... flu in Australia may tip the balance and cause the ... since 1968, agency officials said Tuesday. , Cases in Australia ... in the southern state of Victoria. Rapid spread of the ...

... says , TUESDAY, June 9 (HealthDay News) -- A surge ... the balance and cause the World Health Organization to soon ... Tuesday. , Cases in Australia rose by more than 1,000 ... Victoria. Rapid spread of the virus in a region ...

... Pricing for Workers, Compensation Medicare Set-Aside Arrangement Proposals , ... Centers for Medicare & Medicaid Services (CMS) recently announced ... drug costs in Workers, Compensation Medicare Set-Aside Arrangement (WCMSA) ... compensation warrants prescription drugs for ongoing treatment, CMS, pricing ...

... Solutions, Inc. (Nasdaq: STRM ) today announced financial results for the first ... , , Company wins ... Operating Expenses declined by 16%; , Year-over-Year Backlog ... loss of $0.8 million in Q1 2008; , ...

... of lipoprotein(a) , TUESDAY, June 9 (HealthDay News) -- Yet ... cardiac risk, a new study suggests. , A Danish study ... genes give them high blood levels of a cholesterol-related blood ... to justify treatment to reduce those levels. , "We show ...

... Cancer Society, colorectal cancer, America,s third leading type of ... of all colorectal cancer deaths could be avoided by ... can also be painful, and current diagnostic techniques are ... student of the Department of Physical Electronics at Tel ...

WHO Declaration of Swine Flu Pandemic Looks Imminent WHO Declaration of Swine Flu Pandemic Appears Imminent Thomson Reuters Offers Average Wholesale Pricing Information for Workers' Compensation Drug Claims Streamline Health(R) Solutions Reports First Quarter Results Another Blood Fat Fuels Heart Attack Risk A real-time diagnosis for a treatable cancer

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

Medicine Products:

Hg (Mercury), Hair Hexachlorobenzene, Serum or Plasma HerpeSelect Herpes Simplex Virus Type 2 Herpes Simplex Virus Type 2 Glycoprotein G-Specific Antibody, IgG by ELISA (HerpeSelect), CSF